H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

CSL welcomes historic pandemic agreement

CSL Biotherapies welcomed news overnight of a decision by the World Health Assembly to adopt the Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits. The Framework is the culmination of several years work by a dedicated working group of the World Health Organisation (WHO) and paves the way for greater global collaboration between public and private stakeholders in preparing the world for possible future influenza pandemics.

19 May 2011

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

Early results from the largest cross-sectional national allergy study ever conducted, to be released later this month, demonstrate that food allergies commonly occur in infants and toddlers, while environmental allergies, such as to dust, ragweed and mold, are more common in older children and adults.

From Quest Diagnostics 18 May 2011

WHO Director-General outlines vision for reform in World Health Assembly opening address

WHO Director-General Margaret Chan on Monday laid out her vision for reforming the international health agency in the opening address of the World Health Assembly in Geneva, saying she sees "a WHO that gives a bigger voice to the many partners working on health, but encourages them to speak with a coherent voice that responds, first and foremost, to the needs and priorities as defined by recipient countries," Intellectual Property Watch reports.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Concern over vaccine safety prevents parents from vaccinating asthmatic children

Concern over vaccine safety is one of the primary factors preventing parents from having their asthmatic children vaccinated for influenza, or flu, according to Michigan researchers. Parents who do not vaccinate their children are also less likely to view flu as a"trigger" for their child's asthma, the researchers noted.

17 May 2011

Computationally designed antiviral proteins may fight against influenza

A research article May 12 in Science demonstrates the use of computational methods to design new antiviral proteins not found in nature, but capable of targeting specific surfaces of flu virus molecules.

16 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011.

13 May 2011

Increase in public health spending linked with reduction of pandemic influenza mortality

Pandemic A (H1N1) 2009 mortality rates exhibited wide diversion between countries. Based on data from a total of 30 European countries, a study published in the journal PLoS ONE found that the greater the state financial "generosity" to health sector the lower the pandemic influenza mortality.

13 May 2011

Winner Medical second quarter net sales increase 27% to $33.2 million

Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton products in China, today reported consolidated financial results for the second quarter ended March 31, 2011.

11 May 2011

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Aethlon Medical, Inc. announces that it has submitted a request to the U.S. Food and Drug Administration for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlon Hemopurifier in the United States.

10 May 2011

Novavax first quarter net loss decreases to $7.5 million

Novavax, Inc. today announced its financial results for the first quarter ended March 31, 2011.

9 May 2011

NBA Cares, SAHM and Tulsa Shock guard partner for teen vaccine awareness campaign

Tulsa Shock guard Andrea Riley and Basketball Hall of Famer Bob Lanier teamed up with NBA Cares and the Society for Adolescent Health and Medicine today to bring Vaccines for Teens to the Tulsa community.

5 May 2011

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

NanoViricides' FluCide drug candidate greatly reduces lung viral load in animals

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal level of influenza virus infection.

3 May 2011

Pregnant women with H1N1 more likely to have low birth weight baby

In 2009, the United States was gripped by concern for a new winter threat: the H1N1 strain of influenza. According to research conducted through that winter, pregnant women were right to be concerned.

3 May 2011

MedImmune abstracts on influenza and RSV to be presented at PAS meeting

MedImmune announced today it will present 11 abstracts at the Pediatric Academic Societies Meeting at the Colorado Convention Center in Denver, CO, April 30 - May 3, 2011.

2 May 2011

PURE named winner of CSN 2011 National Child Safety Award

PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate antimicrobial, today announced that Child Safety Network has named PURE the winner of its 2011 National Child Safety Award and has granted PURE Hard Surface disinfectant its Safe Family Seal of Approval.

30 Apr 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

Study finds low pediatric flu vaccination acceptance rates in Atlanta

A study of H1N1 and seasonal influenza vaccination in a sample of black and Hispanic children in Atlanta found a low rate of vaccine acceptance among parents and caregivers.

29 Apr 2011

H1N1 News and Research

CSL welcomes historic pandemic agreement

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

WHO Director-General outlines vision for reform in World Health Assembly opening address

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Concern over vaccine safety prevents parents from vaccinating asthmatic children

Computationally designed antiviral proteins may fight against influenza

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

Sinovac first quarter sales increase 5.3% to $4.7 million

Increase in public health spending linked with reduction of pandemic influenza mortality

Winner Medical second quarter net sales increase 27% to $33.2 million

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Novavax first quarter net loss decreases to $7.5 million

NBA Cares, SAHM and Tulsa Shock guard partner for teen vaccine awareness campaign

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

NanoViricides' FluCide drug candidate greatly reduces lung viral load in animals

Pregnant women with H1N1 more likely to have low birth weight baby

MedImmune abstracts on influenza and RSV to be presented at PAS meeting

PURE named winner of CSN 2011 National Child Safety Award

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

Study finds low pediatric flu vaccination acceptance rates in Atlanta

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News